bionews vol 17
TRANSCRIPT
-
7/29/2019 Bionews Vol 17
1/2
ation using Autoclave
Plan Execute Test
Changes in Dowsntream Processing
The biopharmaceutical industry relies on change to make progress in a commercial environment thatsimultaneously demands higher productivity, higher quality, and lower costs. Recombinant protein titers haveimproved from tens of milligrams to more than 10 grams per liter during the past 20 years, and at the sametime, batch volumes have increased so that industry faces the real prospect of batch yields exceeding 100 kg ofprotein in the next decade. Over the same period, regulatory demands have become more onerous, and thepressure to reduce costs has increased as more biopharmaceuticals come off patent and overseasmanufacturers begin to take an interest in Western markets.
There is no doubt that progress in the industry has been impressive [...]. Most of the increases in productivitythat have been achieved in previous decades have resulted from improvements in the upstream productionphase, with (1) more efficient bioreactors, (2) better media formulations and (3) cell lines that areintrinsically more productive due to the development [...].
Downstream processing is now routinely found to be the bottleneck in biopharmaceutical manufacturingbecause its capacity has not kept pace with upstream production. [...] Whereas upstream production can bescaled up almost indefinitely by increasing the productivity of cells growing in a bioreactor, downstreamprocessing has limits imposed by physics and chemistry. Downstream processing is driven by the mass ofproduct. If one makes more product per batch, one needs correspondingly larger volumes of buffer, largerstorage tanks, preparation areas, larger filters, and most importantly, larger amounts of chromatography
media. [...]
How can this productivity dilemma be addressed? [...] Three solutions are currently being considered bymanufacturers: a) the streamlining of existing processes, b) the revisiting of simple technology solutionscurrently employed in the bulk-chemical industry and c) the use of innovative technologies from thebiopharmaceutical research sector.
a) Antibody manufacturing provides an excellent example of the application of process redesign andstreamlining principles to increase productivity, cut costs, and maintain product quality: Most manufacturersuse three chromatography steps for antibody purification:
Protein A capture step
Anion exchange (AEX)chromatography step to
extract negatively chargedcontaminants
Cation exchange (CEX) chromatography or hydrophobicinteraction chromatography (HIC) to remove positively
charged residual contaminants and product relatedimpurities
[...] Pfizer [...] introduced two types of process modifications, one in which the order of the polishing stepswas reversed and another in which different separation technologies were used to increase process capacity(i.e., using membrane absorbers). These changes increased the efficiency of purification to such an extentthat, for some antibody products, the cation-exchange step became unnecessary, reducing the process fromthree columns to two columns or even a single column. Not only did this save the direct costs of column resinand buffers, but also reduced the process time by > 45% which doubled the productivity in terms of batchprocessing.
b) Precipitation is widely used as a purification approach in the bulk-chemical industry [...] Precipitationhas therefore been used to remove soluble impurities from the feed stream during antibody manufacturing,
and these solids can then be trapped by filtration or pelleted by centrifugation leaving a clear feed streamrelatively enriched for the target protein. [...]
c) Innovative technologies from the biopharmaceutical research sector would include membranechromatography, disposable technology... which would allow to switch to new campaigns rapidly and toproduce multiple products and hence might be the answer to the new biopharmaceutical paradigm.
Refer the complete article / references from Biopharm September 2011
ISSUE no.17NOVEMBER 2011 BiONEWS
-
7/29/2019 Bionews Vol 17
2/2
eedbacPartici
What Ioutstanhe wayas been
interatheoprac
ogetherther uthe tr
sect
Mr. Sihl
BI, Sout
Theter
Pr
E
pr
BI
r
from apant:
foundding isBiozeenable to
t they &ical. This isusual inining
or
e from
h Africa
BITPdvancedLomtrainingiductionanngineering,grammedaP,isopentindividualegistration
IntroduMarket
ProductProspecDrug DeSteps in
MicrobiFermenAeratioInoculuMicrobi
Cell CuGood laPrimaryNutritioCryopre
DownstPrinciplPrincipl
ChromaProtein
SterilizPrinciplPrinciplCold stFilter In
UPCO
Over
Over
Adva
ng
s
OVERVI
Theo
ction to the
Share
stsvelopmentPharma-Bio
al Ferment
tor Principle& AgitatioDevelopm
l growth
ture
boratory ancultures tonal requireservation p
ream Proce
es of Centries of Tange
tography baquantificati
tion & Filt
es of Moistes of Dry Herilization btegrity Test
ING EVENTS
iew of Bioph
iew of Bioph
ced Training
SHORT
EW OF
ry sessions
biopharma
rocessestech Produc
tion
s & Designand KLa Es
ent
cell culturestablishedents of cul
inciples and
ssing
ugationtial Flow Fi
sicson methods
ation Tech
eat Sterilizat Sterilizatfiltration
ing
Progr
armaceutical
armaceutical
in Biopharma
ERM TR
BIOPH
sector
tion
timation
practicescell linesured cellscell bankin
ltration
iques
tionion
m
production
production
production
INING
RMACE5 WEEKS
InoculuFermenFermenGrowthFermen
AsepticCell quSub-culEstablisCryopre
ClarificProtein
ProteinProtein
OperatiAutoclaSterilizSterilizIT of hy
batch 1
batch 2
nd Engineeri
ECEMBE
UTICAL
P
build uptor inoculattor samplinrate estimator harvest
techniquesntitation a
turing of mohment andservation a
tion of cellconcentrati
purificationquantificati
on of industve)tion In Plaction of Meddrophobic a
Durat
2 to 5
2 to 5
g 6 mo
ContactHennur BBangaloreTel:+91 8Web:www.Mail : trai
R 2011
PRODU
actical sess
ion
tionand cleanin
in cell cultud examinatinolayer cultonitoring o
d revival of
brothon
on
rial sterilize
e for procesia by Sterilind hydrophi
ion
eeks 28
eeks 12
ths 2 J
usgalur road, G- 560077
653 09 009biozeen.comingenquiry@
CTION
ions
reonuresf Suspensiofrozen cells
rs (DHS and
s vesseling grade fi
lic filters
Start Date
ov11 to 30
ec11 to 13
an12 to 29 J
ubbi cross
iozeen.com
culture
lters
ec11
an11
n12